Sector News

AstraZeneca aims to go carbon free by 2025—and it’ll spend $1B to do it

January 24, 2020
Life sciences

For a pharma company selling respiratory drugs, climate change would probably mean more patients and increased sales. But AstraZeneca has committed to contributing its fair share to stop that trend.

Just as the topic of climate change takes center stage at the World Economic Forum in Davos, Switzerland, AstraZeneca unveiled its Ambition Zero Carbon program, which aims to achieve zero carbon emissions from its global operations by 2025.

To do that, it will invest up to $1 billion, part of which will go toward developing next-generation respiratory inhalers that have almost no negative impact on global warming, the company said.

It’s the latest move by a drugmaker to cut its carbon footprint—a trend that’s become more common of late but is still far from usual across the pharma industry. The number of drug companies winning kudos for their sustainability work amounts to less than a dozen.

“I believe we’re facing a climate crisis, and every company has to do something,” AstraZeneca CEO Pascal Soriot said in an interview with Bloomberg. “I have children and a grandson, and they’re going to look at me and say, ‘what did you do?’ And our employees also are asking us, expecting us to do something.”

The new pressurized metered-dose inhalers AZ promises to develop for asthma and chronic obstructive pulmonary disease will use propellants with a Global Warming Potential mark that’s 90% to 99% lower than the older ones.

To achieve zero carbon emissions by 2025, AstraZeneca plans to turn all of its energy consumption to renewable sources for both power and heat and switch to electric cars.

Beyond its own company, the British drugmaker promises to ask its suppliers to cut carbon emissions so that it can become carbon negative along its entire value chain by 2030.

The plan, which according to AstraZeneca accelerates its decarbonization gloals by more than a decade, also includes the AZ Forest project in which the company will partner with reforestation organizations and governments to plant 50 million trees over the next five years.

The renewed commitment comes on the heels of AZ being recognized by global environmental impact nonprofit CDP on its annual “A List” for corporations leading on environmental transparency and performance. Among the 179 companies that made this year’s list are Bayer, Baxter, Eisai, Johnson & Johnson, Lundbeck, Novo Nordisk and Ono Pharmaceutical.

Environmental sustainability has become an increasingly common theme within the pharma industry as companies work to establish a responsible corporate image before the public. With this year’s Davos meeting revolving around climate change, more companies may join in with their own announcements.

Already, at this year’s J.P. Morgan Healthcare Conference, Takeda CEO Christophe Weber said the Japanese pharma is aiming to be carbon neutral this year by offsetting 4.5 million tons of emissions. “It’s a financial commitment that we can do without changing our financial target, and that’s because we have reduced in the past our carbon emissions,” he said.

Last year, Novo Nordisk said (PDF) it was on track to use only renewable electricity at its production facilities by 2020. The goal will be enabled by the installation of a 672-acre solar panel group in North Carolina, which will provide power to the Danish company’s entire U.S. operations from early 2020.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.